<img alt="" src="https://secure.perk0mean.com/180803.png" style="display:none;">

Collaborating to End Racial Disparities in Clinical Trials

Download the Free Whitepaper to Learn How Biopharma and Health Centers Can Come Together to Improve Health Equity

In this Whitepaper

The American population is increasingly racially and ethnically diverse: the 2010 US Census reported four “minority-majority” states, including Texas, California, Hawaii, and New Mexico. However, clinical trials have struggled to reflect the diversity of our nation. This truth has concerning downstream implications: First, clinical research suffers. Second, the healthcare community falls short of its collective goal to achieve health equity.

Health centers, which serve a higher percentage of racially diverse populations, may be the "missing link" in making sure drugs and vaccines are safe and effective for the entire US population. A workable solution, however, must align with the the health center mission, respect the population's unique concerns and require minimal change to existing operations.

Discussion Points & Takeaways
  • The downstream effects of a lack of socioeconomic, racial, and cultural diversity in clinical trials
  • The socioeconomic and racial diversity of health center patient populations
  • How health centers can assert a role in clinical research that helps achieve health equity for their patients

In discussing each of these areas, par8o sets the foundation for the par8o Research Network (PRN), a groundbreaking endeavor to improve disparity in healthcare treatment options accessible by the nation’s health center patients.

PRN Whitepaper iPad less margin

Download the Whitepaper